|   | 
        
            
         | 
          | 
        
        
        
            | 
                
             | 
         
        
             | 
         
        
            
            
            
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    ¹Âſũ¸²  MUTON CREAM[Crotamiton , Dipotassium glycyrrhizinate , Lidocaine , Miconazole nitrate]  
                    
                 | 
               
              
                | 
                     ÀϹÝÀǾàǰ | ¹Ì»ý»ê  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |  
                              
                                  | 
                                   | 
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   |  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
            ºñ±Þ¿©
          
        
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ´ã¹é»öÀÇ Å©¸²Á¦  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    1's | 
   
  
  
  
  
  
  
  
  
  
  
  
  
   
    | º¸°ü¹æ¹ý | 
    Â÷±¤, ±â¹Ð¿ë±â | 
   
  
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
      
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
     
    
     
	 
      Á·ºÎ¹é¼±(¹«Á»), °íºÎ¹é¼±(¿Ï¼±), ¼Ò¼öÆ÷¼º ¹Ý»ó¹é¼±
      
      
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      [ÁÖ¼ººÐÄÚµå:343900CCM ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] 
1ÀÏ 1ȸ, ȯºÎ¿¡ Àû´ç·®À» µµÆ÷ÇÑ´Ù. 
[Á¦Çüº°º¹¾àÁöµµ]     
      	    
     | 
   
  
  
  
   
    | ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë | 
    
        
	  [º¸±â]
     | 
   
  
  
  
  
   
    | °æ°í | 
    
      ¾àÀ̳ª ÈÀåǰµî¿¡ ÀÇÇÑ ¾Ë·¹¸£±âÁõ»óÀÌ ³ªÅ¸³ ÀûÀÌ Àִ ȯÀÚ, ȯºÎ°¡ ¾È¸éÀ̰ųª ±¤¹üÀ§ÇÑ È¯ÀÚ, ½ÀÀ±À̳ª Áø¹«¸§ÀÌ ½ÉÇÑ È¯ÀÚ, À¯¡¤À¯¾Æ.
     | 
   
  
  
  
  
   
    | ±Ý±â | 
    
      - ´«À̳ª ´«ÁÖÀ§, Á¡¸·(¿¹:
  ±¸°, ºñ°, Áú µî),À½³¶, ¿ÜÀ½ºÎ
½ÀÁø, À½ºÎÀÇ ½ÀÁø
     | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    - ¾àÀ̳ª ÈÀåǰ µî¿¡ ÀÇÇÑ ¾Ë·¹¸£±â Áõ»ó(¿¹:
  ¹ßÁø, ¹ßÀû, °¡·Á¿ò, ÇǺκ´ µî)ÀÌ ³ªÅ¸³ ÀûÀÌ Àִ ȯÀÚ
ȯºÎ°¡ ¾È¸éÀ̰ųª ±¤¹üÀ§ÇÑ È¯ÀÚ
½ÀÀ±À̳ª Áø¹«¸§ÀÌ ½ÉÇÑ È¯ÀÚ
À¯,À¯¾Æ
ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. | 
   
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      ÀÌ ¾àÀÇ »ç¿ë¿¡ ÀÇÇØ ÇǺκ´, Àڱذ¨, ¹ßÁø ¹ßÀû, Áø¹«¸§, °¡·Á¿ò, °ÇÁ¶,´ç±â´Â ´À³¦, ³«¼³ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì »ç¿ëÀ» ÁßÁöÇϰí Àǻ糪 ¾à»ç¿Í »óÀÇÇÑ´Ù.
          
     | 
   
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
     1) Á¤ÇØÁø ¿ë¹ý․¿ë·®À» Àß ÁöŲ´Ù. 
 2) ¼Ò¾Æ¿¡°Ô »ç¿ëÇÒ °æ¿ì¿¡´Â º¸È£ÀÚÀÇ Áöµµ․°¨µ¶ÇÏ¿¡ »ç¿ëÇÑ´Ù. 
 3) 2ÁÖ Á¤µµ Åõ¿© ÈÄ¿¡µµ Áõ»óÀÇ °³¼±ÀÌ º¸ÀÌÁö ¾ÊÀ» °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù. 
 4) ¿ÍÆÄ¸°À¸·Î Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚÀÇ °æ¿ì¿¡´Â ÃâÇ÷ ¶Ç´Â ¸ÛÀÌ ¹ß»ýÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ¾àÀ» º¹¿ëÇϱâ Àü¿¡ ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù. 
 | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    - ¾î¸°ÀÌÀÇ ¼Õ¿¡ ´êÁö ¾Ê´Â Àå¼Ò¿¡ º¸°üÇÒ °Í
 - Á÷»çÀϱ¤À» ÇÇÇÏ°í µÉ ¼ö ÀÖ´Â ÇÑ ½À±â°¡ ÀûÀº ¼´ÃÇÑ °÷¿¡ º¸°üÇÒ °Í
 - ¿À¿ëÀ» ÇÇÇÏ°í ´Ù¸¥ ¿ë±â¿¡ ¹Ù²Ù¾î ³ÖÁö ¸» °Í
 
  | 
   
  	
  
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  
   
    ½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  	
  
  
   
    | Á¦Çüº° º¹¾àÁöµµ | 
    [Å©¸²] | 
   
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | µ¶¼ºÁ¤º¸ | 
    Lidocaine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
Potassium¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  | 
   
  
   
    | Mechanism of Action | 
    
       Crotamiton¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching.
  Lidocaine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.
  Miconazole¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Miconazole interacts with 14-¥á demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Miconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. 
     | 
   
  
   
    | Pharmacology | 
     
       Crotamiton¿¡ ´ëÇÑ Pharmacology Á¤º¸ Crotamiton is usually used to treat pruritis (itching of the skin) caused by scabies or sunburn. Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Due to this cooling effect it is also effective for the relief of sunburn. The drug is also believed to kill scabies through an unknown mechanism.
  Lidocaine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide.
  Miconazole¿¡ ´ëÇÑ Pharmacology Á¤º¸ Miconazole is an anti-fungal medication related to fluconazole (Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox), and clotrimazole (Lotrimin, Mycelex). It is used either on the skin or in the vagina for fungal infections. Miconazole was approved by the FDA in 1974. Miconazole prevents fungal organisms from producing vital substances required for growth and function. This medication is effective only for infections caused by fungal organisms. It will not work for bacterial or viral infections. 
     | 
   
  
   
    | Metabolism | 
    
       Crotamiton¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
  Lidocaine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6)
  Miconazole¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2C9 (CYP2C9)Cytochrome P450 2D6 (CYP2D6) 
     | 
   
  
   
    | Protein Binding | 
    
       Crotamiton¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
  Lidocaine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 60-80%
  Miconazole¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available 
     | 
   
  
   
    | Half-life | 
    
       Crotamiton¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
  Lidocaine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 109 minutes
  Miconazole¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available 
     | 
   
  
   
    | Absorption | 
    
       Crotamiton¿¡ ´ëÇÑ Absorption Á¤º¸ 10 % absorbed when applied locally.
  Lidocaine¿¡ ´ëÇÑ Absorption Á¤º¸ Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent.
  Miconazole¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available 
     | 
   
  
   
    | Pharmacokinetics | 
    
       LidocaineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- È¿°ú¹ßÇö½Ã°£ (1ȸ bolus ¿ë·®À¸·Î¼) : 45-90ÃÊ
	
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 10-25ºÐ
	
 - ºÐÆ÷ (Vd) : ¸¹Àº ¿äÀο¡ µû¶ó º¯ÈµÇ¸ç, ¿ïÇ÷¼º ½ÉºÎÀü°ú °£Áúȯ¿¡¼´Â ºÐÆ÷¿ëÀûÀÌ °¨¼ÒµÊ
	
 - ´Ü¹é°áÇÕ : 60-80%, ¥á1-acid glycoprotein°ú °áÇÕ
	
 - ´ë»ç : °£¿¡¼ 90% ´ë»ç  
	
		- Ȱ¼ºÇü ´ë»çüÀÎ  monoethylglycinexylidide(MEGX)¿Í glycinexylidide(GX)°¡ ÃàÀûµÇ¾î ÁßÃ߽Űæ°è µ¶¼ºÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù.
 
	  
	 - ¹Ý°¨±â (biphasic) : ¿ïÇ÷¼º ½ÉºÎÀü, °£Áúȯ, ¼îÅ©, ÁßÁõÀÇ ½ÅÁúȯ¿¡¼ Áõ°¡
	
		- Ãʱâ : 7-30ºÐ
		
 - ¸»±â : ¿µ¾Æ, ¹Ì¼÷¾Æ : 3.2½Ã°£,   ¼ºÀÎ : 1.5-2½Ã°£
    
 Miconazole nitrateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- ´Ü¹é°áÇÕ : 91-93%
 
 - ´ë»ç : °£´ë»ç
 
 - ¹Ý°¨±â : Multiphasic
-    Ãʱâ : 40ºÐ
 
 -    Secondary : 126ºÐ	
 
 -    Terminal : 24½Ã°£
   
 - ¼Ò½Ç : 50%±îÁö º¯¹è¼³, 1% ¹Ì¸¸ÀÌ ¹Ìº¯Èü·Î ½Å¹è¼³
   
     | 
   
  
   
    | Biotransformation | 
    
       Crotamiton¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
  Lidocaine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Primarily hepatic.
  Miconazole¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available 
     | 
   
  
   
    | Toxicity | 
    
       Crotamiton¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
  Lidocaine¿¡ ´ëÇÑ Toxicity Á¤º¸ The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
  Miconazole¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, mouse: LD50 = 3800 mg/kg; Oral, rat: LD50 = 3 gm/kg. Ingestion of the amounts of the components contained in a tube of cream are unlikely to produce overdosage and toxic effects. 
     | 
   
  
   
    | Drug Interactions | 
    
       Crotamiton¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acetohexamide	The beta-blocker decreases the symptoms of hypoglycemiaChlorpropamide	The beta-blocker decreases the symptoms of hypoglycemiaCimetidine	Cimetidine increases the effect of the beta-blockerClonidine	Increased hypertension when clonidine stoppedDisopyramide	The beta-blocker increases toxicity of disopyramideGliclazide	The beta-blocker decreases the symptoms of hypoglycemiaGlipizide	The beta-blocker decreases the symptoms of hypoglycemiaGlisoxepide	The beta-blocker decreases the symptoms of hypoglycemiaGlibenclamide	The beta-blocker decreases the symptoms of hypoglycemiaGlycodiazine	The beta-blocker decreases the symptoms of hypoglycemiaInsulin	The beta-blocker decreases the symptoms of hypoglycemiaLidocaine	The beta-blocker increases the effect and toxicity of lidocainePropafenone	Propafenone increases the effect of beta-blockerRepaglinide	The beta-blocker decreases the symptoms of hypoglycemiaRifampin	Rifampin decreases the effect of the metabolized beta-blockerTelithromycin	Telithromycin may possibly increase metoprolol effectTolazamide	The beta-blocker decreases the symptoms of hypoglycemiaTolbutamide	The beta-blocker decreases the symptoms of hypoglycemiaAmobarbital	The barbiturate decreases the effect of metabolized beta-blockerAprobarbital	The barbiturate decreases the effect of metabolized beta-blockerButalbital	The barbiturate decreases the effect of metabolized beta-blockerButabarbital	The barbiturate decreases the effect of metabolized beta-blockerButethal	The barbiturate decreases the effect of metabolized beta-blockerDihydroquinidine barbiturate	The barbiturate decreases the effect of metabolized beta-blockerHeptabarbital	The barbiturate decreases the effect of metabolized beta-blockerHexobarbital	The barbiturate decreases the effect of metabolized beta-blockerMethohexital	The barbiturate decreases the effect of metabolized beta-blockerMethylphenobarbital	The barbiturate decreases the effect of metabolized beta-blockerPentobarbital	The barbiturate decreases the effect of metabolized beta-blockerPhenobarbital	The barbiturate decreases the effect of metabolized beta-blockerPrimidone	The barbiturate decreases the effect of metabolized beta-blockerQuinidine barbiturate	The barbiturate decreases the effect of metabolized beta-blockerSecobarbital	The barbiturate decreases the effect of metabolized beta-blockerTalbutal	The barbiturate decreases the effect of metabolized beta-blockerCitalopram	The SSRI increases the effect of the beta-blockerEscitalopram	The SSRI increases the effect of the beta-blockerFluoxetine	The SSRI increases the effect of the beta-blockerSertraline	The SSRI increases the effect of the beta-blockerParoxetine	The SSRI increases the effect of the beta-blockerDihydroergotamine	Ischemia with risk of gangreneDihydroergotoxine	Ischemia with risk of gangreneErgonovine	Ischemia with risk of gangreneErgotamine	Ischemia with risk of gangreneMethysergide	Ischemia with risk of gangreneVerapamil	Increased effect of both drugsHydralazine	Increased effect of both drugsDiltiazem	Increased risk of bradycardiaEpinephrine	Hypertension, then bradycardiaFenoterol	AntagonismFormoterol	AntagonismIsoproterenol	AntagonismOrciprenaline	AntagonismPirbuterol	AntagonismPrazosin	Risk of hypotension at the beginning of therapyProcaterol	AntagonismSalbutamol	AntagonismSalmeterol	AntagonismTerbutaline	AntagonismIbuprofen	Risk of inhibition of renal prostaglandinsIndomethacin	Risk of inhibition of renal prostaglandinsPiroxicam	Risk of inhibition of renal prostaglandins
  Lidocaine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
  Miconazole¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Warfarin	Vaginal miconazole increases the anticoagulant effectAcenocoumarol	Vaginal miconazole increases the anticoagulant effectDicumarol	Vaginal miconazole increases the anticoagulant effectAnisindione	Vaginal miconazole increases the anticoagulant effect 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Crotamiton¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
  Lidocaine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
  Miconazole¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Crotamiton¿¡ ´ëÇÑ Description Á¤º¸ Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.
  Lidocaine¿¡ ´ëÇÑ Description Á¤º¸ A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem]
  Miconazole¿¡ ´ëÇÑ Description Á¤º¸ An imidazole antifungal agent that is used topically and by intravenous infusion. [PubChem] 
     | 
   
  
   
    | Dosage Form | 
    
       Crotamiton¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream	Topical
  Lidocaine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol	TopicalAerosol, metered	TopicalCream	TopicalGel	TopicalJelly	TopicalJelly	UrethralLiquid	BuccalLiquid	DentalLiquid	InfiltrationLiquid	IntravenousLiquid	OralLiquid	TopicalLotion	TopicalOintment	TopicalSolution	InfiltrationSolution	IntramuscularSolution	IntravenousSolution	OralSolution	TopicalSpray	TopicalSwab	Topical
  Miconazole¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol	TopicalCream	IntravaginalCream	TopicalSuppository	Intravaginal 
     | 
   
  
   
    | Drug Category | 
    
       Crotamiton¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antiparasitic AgentsAntipruriticsPesticidesScabicides
  Lidocaine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnestheticsAnesthetics, LocalAnti-Arrhythmia AgentsAntiarrhythmic Agents
  Miconazole¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antifungal Agents 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Crotamiton¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(C(=O)C=CC)C1=CC=CC=C1C
  Lidocaine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
  Miconazole¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Crotamiton¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(C(=O)\C=C\C)C1=CC=CC=C1C
  Lidocaine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
  Miconazole¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ ClC1=CC(Cl)=C(CO[C@@H](CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1 
     | 
   
  
   
    | InChI Identifier | 
    
       Crotamiton¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3
  Lidocaine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)/f/h15H
  Miconazole¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Crotamiton¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N-ethyl-N-(2-methylphenyl)but-2-enamide
  Lidocaine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-diethylamino-N-(2,6-dimethylphenyl)acetamide
  Miconazole¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole 
     | 
   
  
   
    | Drug-Induced Toxicity Related Proteins | 
    
      DOCA ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Aquaporin-2 Drug:DOCA Toxicity:hypertension.  [¹Ù·Î°¡±â] LIDOCAINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:glucose-regulated protein  Drug:lidocaine Toxicity:intestinal disorder.  [¹Ù·Î°¡±â] Replated Protein:Alkaline phosphatase Drug:lidocaine  Toxicity:lidocaine induced hepatitis.  [¹Ù·Î°¡±â] Replated Protein:C-reactive protein Drug:lidocaine  Toxicity:fever.  [¹Ù·Î°¡±â] Replated Protein:C-reactive protein Drug:lidocaine  Toxicity:lidocaine induced hepatitis.  [¹Ù·Î°¡±â] Replated Protein:Alpha-1-acid glycoprotein Drug:lidocaine  Toxicity:lidocaine tolerance.  [¹Ù·Î°¡±â] Replated Protein:Gamma-glutamyltranspeptidase  Drug:lidocaine  Toxicity:fever.  [¹Ù·Î°¡±â] Replated Protein:Alkaline phosphatase Drug:lidocaine  Toxicity:fever.  [¹Ù·Î°¡±â] Replated Protein:Gamma-glutamyltranspeptidase  Drug:lidocaine  Toxicity:lidocaine induced hepatitis.  [¹Ù·Î°¡±â] 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2017-08-04
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
 |  
             
             | 
         
         
         | 
         |